📊 AIMDW Key Takeaways
Is Ainos, Inc. (AIMDW) a Good Investment?
Ainos is a financially distressed pharmaceutical company experiencing severe operational deterioration with revenue collapsing 83% YoY while burning cash at an alarming rate. The company's negative operating margin of -8574.8% and free cash flow of -3.8M indicate unsustainable operations with minimal revenue generation relative to expenses. With only 1.1M in cash and ongoing cash burn, the company faces imminent liquidity crisis unless it can dramatically reverse its business trajectory.
Ainos shows very weak fundamentals: revenue is extremely small and declined 83% year over year, while operating and net losses remain massive relative to sales. Although the balance sheet is not highly leveraged and near-term liquidity ratios look acceptable, cash is low versus ongoing cash burn, making the current business model appear unsustainable without significant improvement in commercialization or additional financing.
Why Buy Ainos, Inc. Stock? AIMDW Key Strengths
- Positive gross margin of 82.6% suggests potential product profitability if revenue scales
- Current ratio of 2.96x provides short-term liquidity cushion
- Zero long-term debt eliminates refinancing risk
- High gross margin suggests the core product mix can support attractive unit economics if revenue scales
- Current and quick ratios indicate adequate short-term balance sheet liquidity at the latest reporting date
- No meaningful long-term debt reduces financial leverage risk
AIMDW Stock Risks: Ainos, Inc. Investment Risks
- Revenue collapsed 83% YoY with only 113K in trailing revenue, indicating complete loss of market demand
- Operating cash flow of -3.8M with only 1.1M in cash provides less than 3 months of runway at current burn rate
- Negative ROE of -102.6% and ROA of -45.4% demonstrate value destruction and operational failure
- Operating margin of -8574.8% indicates the company cannot support its cost structure with current revenue levels
- Dramatic EPS deterioration to -2.61 despite modest YoY improvement signals ongoing value destruction
- Revenue collapse and minimal sales base indicate poor growth quality and weak commercial traction
- Extreme negative operating and net margins show the company is far from profitable
- Low cash relative to negative operating cash flow raises a substantial funding and dilution risk
Key Metrics to Watch
- Monthly cash burn rate and cash runway duration
- Revenue stabilization and return to growth trajectory
- Operating expense reduction initiatives or restructuring plans
- Product pipeline clinical trial progress and commercialization timelines
- Quarterly revenue growth and evidence of sustained commercialization
- Operating cash burn versus cash and equivalents runway
Ainos, Inc. (AIMDW) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.96x current ratio provides a solid financial cushion.
AIMDW Profit Margin, ROE & Profitability Analysis
AIMDW vs Healthcare Sector: How Ainos, Inc. Compares
How Ainos, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Ainos, Inc. Stock Overvalued? AIMDW Valuation Analysis 2026
Based on fundamental analysis, Ainos, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Ainos, Inc. Balance Sheet: AIMDW Debt, Cash & Liquidity
AIMDW Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Ainos, Inc.'s revenue has declined by 79% over the 5-year period, indicating business contraction. The most recent EPS of $-7.82 indicates the company is currently unprofitable.
AIMDW Revenue Growth, EPS Growth & YoY Performance
AIMDW Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.2K | -$2.9M | $-0.64 |
| Q2 2025 | $4.7K | -$3.2M | $-0.99 |
| Q1 2025 | $20.7K | -$3.3M | $-0.21 |
| Q3 2024 | $20.7K | -$3.0M | $-0.33 |
| Q2 2024 | $20.7K | -$2.3M | $-0.49 |
| Q1 2024 | $20.7K | -$2.5M | $-0.57 |
| Q3 2023 | $24.5K | -$3.0M | N/A |
| Q2 2023 | $28.6K | -$2.0M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Ainos, Inc. Dividends, Buybacks & Capital Allocation
AIMDW SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Ainos, Inc. (CIK: 0001014763)
📋 Recent SEC Filings
❓ Frequently Asked Questions about AIMDW
What is the AI rating for AIMDW?
Ainos, Inc. (AIMDW) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 94% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AIMDW's key strengths?
Claude: Positive gross margin of 82.6% suggests potential product profitability if revenue scales. Current ratio of 2.96x provides short-term liquidity cushion. ChatGPT: High gross margin suggests the core product mix can support attractive unit economics if revenue scales. Current and quick ratios indicate adequate short-term balance sheet liquidity at the latest reporting date.
What are the risks of investing in AIMDW?
Claude: Revenue collapsed 83% YoY with only 113K in trailing revenue, indicating complete loss of market demand. Operating cash flow of -3.8M with only 1.1M in cash provides less than 3 months of runway at current burn rate. ChatGPT: Revenue collapse and minimal sales base indicate poor growth quality and weak commercial traction. Extreme negative operating and net margins show the company is far from profitable.
What is AIMDW's revenue and growth?
Ainos, Inc. reported revenue of $113.0K.
Does AIMDW pay dividends?
Ainos, Inc. does not currently pay dividends.
Where can I find AIMDW SEC filings?
Official SEC filings for Ainos, Inc. (CIK: 0001014763) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AIMDW's EPS?
Ainos, Inc. has a diluted EPS of $-2.61.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AIMDW a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Ainos, Inc. has a STRONG SELL rating with 94% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AIMDW stock overvalued or undervalued?
Valuation metrics for AIMDW: ROE of -102.6% (sector avg: 15%), net margin of -9,114.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AIMDW stock in 2026?
Our dual AI analysis gives Ainos, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AIMDW's free cash flow?
Ainos, Inc.'s operating cash flow is $-3.8M, with capital expenditures of $36.1K. FCF margin is -3,358.0%.
How does AIMDW compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -9,114.5% (avg: 12%), ROE -102.6% (avg: 15%), current ratio 2.96 (avg: 2).